Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for Refractory IgA Nephropathy
NCT03633864Phase 2
Key facts
- Status
- Unknown
- Start
- Nov 2017
- Primary completion
- Dec 2020
- Countries
- 1
- Sponsor
- Air Force Medical University
- Modality
- Live Biotherapeutic Products
- Conditions
- IgA nephropathy (IgAN)
01
Overview
Phase 2, open-label trial of allogeneic fecal microbiota in IgA nephropathy (IgAN), sponsored by Air Force Medical University. Status: unknown.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Registry description
IgA nephropathy (IgAN) is one of the most common glomerular diseases worldwide. Current treatments for IgAN are limited by their relatively insufficient efficacy and severe adverse events. Previous studies suggested that the disorder of intestinal flora may play an important role in the pathogenesis and prognosis of IgAN. Fecal microbiota transplantation (FMT) have been proved to be effective on rebuilding the intestinal microecological balance. However, there is no evidence for the safety and efficacy of FMT in IgAN. Therefore, investigators perform a prospective cohort study to evaluate…
Beyond the preview
Go deeper on NCT03633864.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03633864.